Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event-Reference-Cited by-同舟云学术

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event

Published:2015-12-17 Issue:25 Volume:126 Page:2665-2675
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Burns David M.¹,Tierney Rose¹,Shannon-Lowe Claire¹,Croudace Jo¹,Inman Charlotte¹,Abbotts Ben¹,Nagra Sandeep²,Fox Christopher P.³,Chaganti Sridhar²,Craddock Charles F.²,Moss Paul¹,Rickinson Alan B.¹,Rowe Martin¹,Bell Andrew I.¹

Affiliation:

1. School for Cancer Sciences, University of Birmingham, Birmingham, United Kingdom;

2. Centre for Clinical Haematology, University Hospitals Birmingham National Health Service Trust, Birmingham, United Kingdom; and

3. Centre for Clinical Haematology, Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom

Abstract

Key PointsCD19+CD27+ memory B cells are detectable at supranormal frequencies in patients with high-level EBV DNAemia following allogeneic HSCT. These memory B cells are frequently positive for EBV genomes and bear many of the hallmarks of lymphoblastoid transformation.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/25/2665/1390150/2665.pdf

Reference55 articles.

1. Epstein-Barr virus: exploiting the immune system.;Thorley-Lawson;Nat Rev Immunol,2001

2. Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory.;Rickinson;Trends Immunol,2014

3. Post-transplant lymphoproliferative disorders.;Gottschalk;Annu Rev Med,2005

4. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.;Rasche;Bone Marrow Transplant,2014

5. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.;Omar;Transpl Infect Dis,2009

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes;International Journal of Molecular Sciences;2023-11-07

2. Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis;Clinical Immunology;2023-09

3. The IPTA Nashville Consensus Conference on Post‐Transplant lymphoproliferative disorders after solid organ transplantation in children: III – Consensus guidelines for Epstein‐Barr virus load and other biomarker monitoring;Pediatric Transplantation;2023-06-09

4. Use of Rituximab in Epstein-Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation;J BIOL REG HOMEOS AG;2023

5. From bedside to bench: how existing therapies inform the relationship between Epstein–Barr virus and multiple sclerosis;Clinical & Translational Immunology;2023-01